Editorial Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/Pharmacol.3.020
COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer
Daniel A. King1, Jeffrey Chi2, Shreya Prasad Goyal2, Muhammad Wasif Saif2,*
- 1Stanford University, Stanford, CA, USA
- 2Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY, USA
Corresponding Author
M. Wasif Saif, wsaif@northwell.edu
Received Date: February 17, 2021
Accepted Date: March 01, 2021
King DA, Chi J, Goyal SP, Saif MW. COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer. Arch Pharmacol Ther. 2021; 3(1):5-9.
Copyright: © 2021 King DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
COVID-19, Cancer patients, Immunosuppressed, Infection
Recommended Articles
Prevalence of Symptom Clusters in Cancer Patients at First Presentation in Palliative Care Clinic as per Different Disease Groups
Cancer has its own disease burden and patients usually suffer from symptom clusters when they are referred for palliative treatment. Identification of symptom cluster trajectories will help clinician to take into account measures that can optimize quality of life of palliative patients. Therefore the aim of this paper is to determine the overall prevalence of symptoms and symptoms clusters in different disease groups according to etiology at the time of first visit to Palliative care clinic by using HIS Palliative First Assessment note indicating Edmonton symptom scale.
Searching for Easy Reliable Prognostic Parametres in Colorectal Cancer Patients Evaluation
Despite the advances in diagnostic and therapeutic field, colorectal cancer (CRC) still remains the third most common cause of death worldwide, with more than 600,000 cancer-related deaths per year.
The Dual Role of Macrophages during Hepatitis B Infection
Hepatitis B virus (HBV) chronically infects more than 250 million individuals worldwide and is responsible for more than 800,000 deaths per year by promoting end-stage liver diseases, among which decompensated cirrhosis and hepatocellular carcinoma (HCC) (WHO, July 2020) are prominent. Studies performed in chimpanzees or in animalversion of HBV (woodchuck HBV: WHBV) highlighted the lack of immune responses against the virus upon primary infection. Thus, HBV has been described as a “stealth” virus (i.e. a virus that does not modify/induce immune response in the cell). However, a growing number of studies describe that HBV is able to rapidly and efficiently counteract the innate immune response in a large variety of cells (hepatocytes, macrophages, Natural Killer cell…). Hereby, we focus on the role of macrophages (Mφ) during HBV infection.
COVID-19 and the Health of Illicit Substance Users: Preliminary Analysis from Illicit Drug Transaction Data
While much attention has been given to how COVID-19 patients are treated (or fail to be treated), the impact of the pandemic on illicit drug users remains largely undiscussed
COVID-19 Rapid Diagnostic Test Results and their Associations with Certain Factors Among the Residents of Balochistan
This paper analyses any possible association of various factors like gender, last COVID-19 PCR test results, BCG Vaccination, Seasonal Flu vaccination, occupation and confirmed case contact history with COVID-19 RDT results of the participants.